$CYRX
Cryoport, Inc. Stock $cyrx

$cyrx Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-K Financial Statement

#000114420416110227 Filed on June 28, 2016

Income Statement

Concept	2016 Q2	2016	2015 Q4
Revenue	$1.918M	$5.882M	$1.459M
YoY Change	34.03%	49.47%	49.64%
Cost Of Revenue	$1.136M	$3.992M	$1.070M
YoY Change	20.41%	44.3%	44.47%
Gross Profit	$782.0K	$1.890M	$384.0K
YoY Change	60.27%	61.71%	63.4%
Gross Profit Margin	40.77%	32.14%	26.32%
Selling, General & Admin	$2.625M	$11.27M	$2.835M
YoY Change	29.56%	75.83%	89.95%
% of Gross Profit	335.73%	596.17%	738.38%
Research & Development	$135.8K	$598.1K	$227.8K
YoY Change	74.72%	69.64%	129.94%
% of Gross Profit	17.37%	31.64%	59.31%
Depreciation & Amortization	$100.0K	$374.2K	$80.00K
YoY Change	118.95%	89.05%	60.0%
% of Gross Profit	12.79%	19.8%	20.83%
Operating Expenses	$2.761M	$11.87M	$3.063M
YoY Change	31.23%	75.5%	92.43%
Operating Profit	-$1.979M	-$8.766M	-$2.679M
YoY Change	22.45%	56.73%	97.42%
Interest Expense	$21.24K	$139.4K	$79.95K
YoY Change	-93.01%	-90.24%	64.48%
% of Operating Profit
Other Income/Expense, Net	-$1.915K	-$4.341M	-$1.347K
YoY Change	96.41%	101668.35%	-29.33%
Pretax Income	-$3.932M	-$13.11M	-$2.760M
YoY Change	104.7%	86.58%	96.07%
Income Tax	$2.484K	$5.673K	$305.00
% Of Pretax Income
Net Earnings	-$3.935M	-$9.820M	-$2.760M
YoY Change	104.49%	39.75%	96.05%
Net Earnings / Revenue	-205.16%	-166.95%	-189.2%
Basic Earnings Per Share
Diluted Earnings Per Share	-$276.8K	-$675.8K	-$381.7K
COMMON SHARES
Basic Shares Outstanding	14.27M shares		7.225M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.500M	$4.500M	$5.200M
YoY Change	87.5%	60.71%	550.0%
Cash & Equivalents	$4.526M	$4.500M	$5.247M
Short-Term Investments
Other Short-Term Assets	$300.0K	$300.0K	$289.0K
YoY Change	13.97%	50.0%	188.97%
Inventory	$100.0K	$100.0K	$52.88K
Prepaid Expenses
Receivables	$1.000M	$1.200M	$616.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.900M	$6.100M	$6.206M
YoY Change	68.02%	48.78%	343.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.400M	$1.600M	$875.7K
YoY Change	267.11%	23.08%	191.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$400.0K	$400.0K	$400.0K
YoY Change		0.0%
Total Long-Term Assets	$1.800M	$2.000M	$1.253M
YoY Change	253.85%	17.65%	150.51%
TOTAL ASSETS
Total Short-Term Assets	$5.900M	$6.100M	$6.206M
Total Long-Term Assets	$1.800M	$2.000M	$1.253M
Total Assets	$7.700M	$8.100M	$7.459M
YoY Change	91.54%	39.66%	292.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.400M	$1.200M	$1.100M
YoY Change	133.33%	-7.69%	57.14%
Accrued Expenses	$400.0K	$400.0K	$400.0K
YoY Change	0.0%	-20.0%	-33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$900.0K	$700.0K	$1.000M
YoY Change	-10.0%	75.0%	-23.08%
Total Short-Term Liabilities	$2.600M	$2.200M	$2.468M
YoY Change	31.8%	0.0%	-17.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities		$200.0K
YoY Change
Total Long-Term Liabilities	$0.00	$200.0K	$0.00
YoY Change		-66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.600M	$2.200M	$2.468M
Total Long-Term Liabilities	$0.00	$200.0K	$0.00
Total Liabilities	$2.600M	$2.400M	$2.468M
YoY Change	31.8%	-11.11%	-17.72%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$114.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.100M	$5.700M	$4.990M
YoY Change
Total Liabilities & Shareholders Equity	$7.700M	$8.100M	$7.459M
YoY Change	91.54%	39.66%	292.56%

Cashflow Statement

Concept	2016 Q2	2016	2015 Q4
OPERATING ACTIVITIES
Net Income	-$3.935M	-$9.820M	-$2.760M
YoY Change	104.49%	39.75%	96.05%
Depreciation, Depletion And Amortization	$100.0K	$374.2K	$80.00K
YoY Change	118.95%	89.05%	60.0%
Cash From Operating Activities	-$1.450M	-$5.719M	-$1.400M
YoY Change	-22.46%	-9.37%	30.84%
INVESTING ACTIVITIES
Capital Expenditures	$193.9K	$1.063M	-$370.0K
YoY Change	76.85%	1415.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$190.0K	-$1.068M	-$370.0K
YoY Change	72.73%	-4.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.380M	$6.064M	-40.00K
YoY Change	14.19%	-31.17%	-102.31%
NET CHANGE
Cash From Operating Activities	-1.450M	-$5.719M	-1.400M
Cash From Investing Activities	-190.0K	-$1.068M	-370.0K
Cash From Financing Activities	3.380M	$6.064M	-40.00K
Net Change In Cash	1.740M	-$722.9K	-1.810M
YoY Change	77.55%	-152.38%	-374.24%
FREE CASH FLOW
Cash From Operating Activities	-$1.450M	-$5.719M	-$1.400M
Capital Expenditures	$193.9K	$1.063M	-$370.0K
Free Cash Flow	-$1.644M	-$6.782M	-$1.030M
YoY Change	-16.96%	6.3%	-3.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Trading Symbol TradingSymbol	CYRX
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14271910	shares
CY2015Q1	us-gaap	Inventory Net InventoryNet	69680	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	2161902	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307926	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	136821	USD
CY2015Q1	us-gaap	Deposits Assets DepositsAssets	0	USD
CY2015Q1	us-gaap	Assets Assets	2606649	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	758696	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	535507	USD
CY2015Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	26452	USD
CY2015Q1	us-gaap	Liabilities Liabilities	3022948	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	5026	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	97346137	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97768079	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-416299	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2606649	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	69801	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	4132055	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2996496	USD
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2016Q1	us-gaap	Liabilities Liabilities	2727853	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	550263	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	10631210	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-8740896	USD
CY2016	us-gaap	Interest Expense InterestExpense	1065942	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9901	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9816739	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3625	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-9820364	USD
CY2016	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	4474348	USD
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	762727	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7339855	shares
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2173578	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	554275	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	12251	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	116214522	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	6761961	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-5593032	USD
CY2015	us-gaap	Interest Expense InterestExpense	1428015	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4266	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7025313	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15057439	USD
CY2016Q1	us-gaap	Assets Assets	5823780	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1271926	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	508754	USD
CY2016Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	392898	USD
CY2016Q1	us-gaap	Deposits Assets DepositsAssets	363403	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113130846	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	5882199	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	3935320	USD
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	3991885	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	2766391	USD
CY2016	us-gaap	Gross Profit GrossProfit	1890314	USD
CY2015	us-gaap	Gross Profit GrossProfit	1168929	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	352580	USD
CY2015	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	4864292	USD
CY2015	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	305328	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12196533	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	239228	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	483058	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1368305	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2884162	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	881706	USD
CY2016	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-168712	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	38509	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2713	USD
CY2016	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	469809	USD
CY2015	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	76587	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	39977	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151392	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-816	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	209138	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-162145	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	271424	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	57954	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6305690	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4127702	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70130	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1119251	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-70130	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	915000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	741377	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	173623	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	50000	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	30120	USD
CY2016	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	292000	USD
CY2015	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	128000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8812281	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5233437	USD
CY2016	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1387340	USD
CY2015	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	1035605	USD
CY2015	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-16423	USD
CY2015	us-gaap	Interest Paid InterestPaid	753	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	3625	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	USD
CY2016	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1766997	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369581	USD
CY2016	us-gaap	Interest Paid InterestPaid	57121	USD
CY2016	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	26901	USD
CY2015	cyrx	Debt Conversion Converted Instrument Related Party Amount Warrant Issued DebtConversionConvertedInstrumentRelatedPartyAmountWarrantIssued	280370	USD
CY2016	cyrx	Fair Value Of Warrants Issued Notes Payable FairValueOfWarrantsIssuedNotesPayable	0	USD
CY2015	cyrx	Fair Value Of Warrants Issued Notes Payable FairValueOfWarrantsIssuedNotesPayable	458937	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3896678	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4607571	USD
CY2016	cyrx	Maturity Period Of Highly Liquid Investments MaturityPeriodOfHighlyLiquidInvestments	P90D
CY2016Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	199190	USD
CY2015Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	159992	USD
CY2016Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	48500	USD
CY2015Q1	cyrx	Accrued Board Of Director Fees Current AccruedBoardOfDirectorFeesCurrent	401532	USD
CY2016Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	0	USD
CY2015Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	2947	USD
CY2016Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	966000	USD
CY2016Q1	us-gaap	Cash Cash	2600000	USD
CY2015Q1	us-gaap	Cash Cash	1300000	USD
CY2016Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12200	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	22100	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	56923	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	41725	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12878	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	27955	USD
CY2016Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	50615	USD
CY2015Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	30746	USD
CY2016Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	301722	USD
CY2015Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	283943	USD
CY2016Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	406471	USD
CY2015Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	23652	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1221696	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1131546	USD
CY2016	us-gaap	Depreciation Depreciation	209100	USD
CY2015	us-gaap	Depreciation Depreciation	154700	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	594502	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	585921	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	701341	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	564520	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30100	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43200	USD
CY2016Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	261064	USD
CY2015Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	161241	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.00
CY2016	cyrx	Discount Price Per Share Percentage DiscountPricePerSharePercentage	0.2	pure
CY2015	cyrx	Class Of Warrant Or Rights Expiration Date ClassOfWarrantOrRightsExpirationDate	2020-03-01
CY2016	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	58500	USD
CY2015	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	33500	USD
CY2016Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6100	USD
CY2015Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	4600	USD
CY2016	cyrx	Estimated Base Rent Under Lease EstimatedBaseRentUnderLease	24700	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	302400	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	311300	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	315000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	134000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	169000	USD
CY2016	cyrx	Consulting Service Fee ConsultingServiceFee	290100	USD
CY2016Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2120000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1554000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	35000	USD
CY2015	cyrx	Consulting Service Fee ConsultingServiceFee	339300	USD
CY2016Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19209000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16830000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	56000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	56000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	20000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21420000	USD
CY2015Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18460000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3338000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2382000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-349000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-187000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	76000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	462000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	184000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	874000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3161000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1235000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2016Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12251313	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12251313	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5026585	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5026585	shares
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5925171	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3497230	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4155776	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2912151	USD
CY2016	cyrx	Loss On Write Off Patents LossOnWriteOffPatents	98086	USD
CY2015	cyrx	Loss On Write Off Patents LossOnWriteOffPatents	0	USD
CY2016	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	363403	USD
CY2015	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-9358	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5938099	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	4474348	USD
CY2015	cyrx	Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued	4864292	USD
CY2016	cyrx	Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation	54813	USD
CY2015	cyrx	Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation	0	USD
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1068055	USD
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1175934	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2397712	shares
CY2016	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	98100	USD
CY2016Q1	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	1287781	USD
CY2015Q1	cyrx	Cryogenic Shippers And Data Loggers CryogenicShippersAndDataLoggers	1034554	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2541437	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1439472	USD
CY2016Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	494848	USD
CY2015Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	66577	USD
CY2016	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	70350	USD
CY2015	cyrx	Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets	0	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	200000	USD
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2304495	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	864306	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2916065	USD
CY2015	cyrx	Stockissued During Period Value New Issues1 StockissuedDuringPeriodValueNewIssues1	1691506	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	92609	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	826919	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	17400	USD
CY2015	cyrx	Adjustments To Additional Paid In Capital Warrant Issued Related Party Notes Payable AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedPartyNotesPayable	280370	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	458937	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2572296	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10881	USD
CY2016	cyrx	Adjustments To Additional Paid In Capital Warrant Issued Related Party Notes Payable AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedPartyNotesPayable	26901	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	150150	USD
CY2015Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	1300000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.00
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	324500	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	334200	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	668400	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2255800	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1766997	USD
CY2016	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	5938099	USD
CY2016	cyrx	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	0	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	216529	USD
CY2016	cyrx	Stockissued During Period Value New Issues1 StockissuedDuringPeriodValueNewIssues1	3896678	USD
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.57
CY2016Q1	cyrx	Number Of Stock Units Issued NumberOfStockUnitsIssued	2090750	shares
CY2016Q1	cyrx	Number Of Stock Units Issued Price Per Unit NumberOfStockUnitsIssuedPricePerUnit	3.25
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	As a result, all outstanding shares of Preferred Stock were automatically exchanged at the Mandatory Exchange Time for such units sold in the Qualified Offering (consisting of one share of Common Stock and one Warrant) at an exchange rate determined by: 1) multiplying the number of shares of Preferred Stock to be exchanged by the Class A Original Issue Price or Class B Original Issue Price (as defined in the Certificates of Designation), or $12.00 per share; 2) adding to the result all dividends then accrued but unpaid on such shares of Preferred Stock to be exchanged of $1,068,100; then 3) dividing the result by $2.60 (which is eighty percent (80%) of the price per unit issued in the Qualified Offering).
CY2016Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	266100	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	270000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2016Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15153193	shares
CY2016	cyrx	Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable	-521056	USD
CY2015	cyrx	Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable	0	USD
CY2016	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2018-03-31
CY2015Q3	dei	Entity Public Float EntityPublicFloat	23081331	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	248729	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	97337	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	521056	USD
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1. Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in" align="justify">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material.  Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical companies, contract manufacturers and university researchers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in"> The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.” </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Going Concern</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements have been prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. At March 31, 2016, we had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">113.1</font> million. During the year ended March 31, 2016, we used cash in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.3</font> million and had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.8</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at March 31, 2016, together with the proceeds from the tender offer completed in April 2016, the rights offering completed in June 2016, and revenues generated from our services will be sufficient to sustain our planned operations through the third quarter of fiscal year 2017; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">®</sup></font> <font style="FONT-SIZE: 10pt">Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management’s inability to successfully achieve significant revenue increases or implement cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, we are seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	280400	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	259600	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20800	USD
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Reclassification</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior period financial statement amounts have been reclassified to conform to the current period presentation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentrations of Credit Risk</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) with basic deposit insurance coverage limits up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per owner. At March 31, 2016 and 2015, the Company had cash balances of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million, respectively, which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	305300	USD
CY2016	cyrx	Warrants Expiration Date WarrantsExpirationDate	2018-12-31
CY2015	cyrx	Adjustments To Additional Paid In Capital Fair Value Of Convertible Debt And Warrants With Conversion Feature AdjustmentsToAdditionalPaidInCapitalFairValueOfConvertibleDebtAndWarrantsWithConversionFeature	0	USD
CY2016	cyrx	Adjustments To Additional Paid In Capital Fair Value Of Convertible Debt And Warrants With Conversion Feature AdjustmentsToAdditionalPaidInCapitalFairValueOfConvertibleDebtAndWarrantsWithConversionFeature	0	USD
CY2015Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-12
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1431000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1437000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1555000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	488000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	436000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	582000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1459000	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	384000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1616000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1822000	USD
CY2016	us-gaap	Preferred Stock Dividend Rate Per Dollar Amount PreferredStockDividendRatePerDollarAmount	0.96
CY2016	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2679000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2624000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.31
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6607000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2665000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3000000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2785000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	937000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	825000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	975000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1198000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	339000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	225000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	235000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	370000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1168000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1375000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1357000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1693000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2297000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1385000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-1408000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-1937000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8600	USD

Files In Submission

Name	View Source	Status
0001144204-16-110227-index-headers.html	Edgar Link	pending
0001144204-16-110227-index.html	Edgar Link	pending
0001144204-16-110227.txt	Edgar Link	pending
0001144204-16-110227-xbrl.zip	Edgar Link	pending
cyrx-20160331.xml	Edgar Link	completed
cyrx-20160331.xsd	Edgar Link	pending
cyrx-20160331_cal.xml	Edgar Link	unprocessable
cyrx-20160331_def.xml	Edgar Link	unprocessable
cyrx-20160331_lab.xml	Edgar Link	unprocessable
cyrx-20160331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
v440971_10k.htm	Edgar Link	pending
v440971_ex21.htm	Edgar Link	pending
v440971_ex23-1.htm	Edgar Link	pending
v440971_ex31-1.htm	Edgar Link	pending
v440971_ex31-2.htm	Edgar Link	pending
v440971_ex32-1.htm	Edgar Link	pending
v440971_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYRX
Cryoport, Inc. Stock $cyrx

2016 Q2 Form 10-K Financial Statement

#000114420416110227 Filed on June 28, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX Cryoport, Inc. Stock $cyrx

2016 Q2 Form 10-K Financial Statement

#000114420416110227 Filed on June 28, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYRX
Cryoport, Inc. Stock $cyrx